Evidence map›Paper›PMID 34117252›Full record

ArticleNature communications2021

SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.

Nanda Kishore Routhu, Narayanaiah Cheedarla, Venkata Satish Bollimpelli, Sailaja Gangadhara, Venkata Viswanadh Edara, Lilin Lai, Anusmita Sahoo, Ayalnesh Shiferaw, Tiffany M Styles, Katharine Floyd and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Nanda Kishore Routhu *Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Narayanaiah Cheedarla *Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Venkata Satish Bollimpelli *Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Sailaja Gangadhara *Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Venkata Viswanadh EdaraEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0001-9321-7839
Lilin LaiEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Anusmita SahooEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Ayalnesh ShiferawEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Tiffany M StylesEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Katharine FloydEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID 0000-0002-0866-6961
Stephanie FischingerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-2307-3379
Caroline AtyeoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7489-0232
Sally A ShinRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-9306-2264
Sanjeev GumberDivision of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Shannon KirejczykDivision of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Kenneth H DinnonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-5553-1616
Vineet D MenacheryDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, USA.ORCID 0000-0001-8803-7606
Mark Tomai3M Corporate Research Materials Laboratory, Saint Paul, MN, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7680-9215
Thomas H VanderfordEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Lisa GralinskiDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0003-1374-8002
Mehul S SutharEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Rama Rao AmaraEmory Vaccine Center, Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. ramara@emory.edu.ORCID 0000-0002-6309-6797
Emory University · USRagon Institute of MGH, MIT and Harvard · USThe University of Texas Medical Branch at Galveston · USUniversity of North Carolina at Chapel Hill · USInfectious Disease Research Institute · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIVR01AI148378 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO · 2019 to 2022
$3.7M
NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI148378NIH HHS P51 OD011132
6 · The paper itself

Abstract

There is a great need for the development of vaccines that induce potent and long-lasting protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with potent adjuvant can enhance the potency and longevity of the antibody response. The receptor binding domain (RBD) of the spike protein is a primary target of neutralizing antibodies. Here, we developed a trimeric form of the RBD and show that it induces a potent neutralizing antibody response against live virus with diverse effector functions and provides protection against SARS-CoV-2 challenge in mice and rhesus macaques. The trimeric form induces higher neutralizing antibody titer compared to monomer with as low as 1μg antigen dose. In mice, adjuvanting the protein with a TLR7/8 agonist formulation alum-3M-052 induces 100-fold higher neutralizing antibody titer and superior protection from infection compared to alum. SARS-CoV-2 infection causes significant loss of innate cells and pathology in the lung, and vaccination protects from changes in innate cells and lung pathology. These results demonstrate RBD trimer protein as a suitable candidate for vaccine against SARS-CoV-2.

Indexed as

Adjuvants, ImmunologicAlum CompoundsAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19COVID-19 VaccinesDisease Models, AnimalHeterocyclic Compounds, 3-RingHumansMacaca mulattaMiceProtein BindingSARS-CoV-2Adjuvants, ImmunologicAlum Compoundsaluminum sulfateAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHeterocyclic Compounds, 3-RingMEDI9197Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Stearic Acids

Identifiers

PMID34117252
PMCPMC8196016
OpenAlexW3170138132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.